Vaderis Therapeutics has secured $152 million in Series B financing to fund the global Phase 3 development of its lead candidate engasertib in hereditary hemorrhagic telangiectasia, or HHT. The Swiss company is positioning the program as the first therapy specifically developed for the rare inherited vascular disorder.
The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, Perceptive Advisors, Kalehua Capital, Medicxi, Droia and EQT Life Sciences. EQT invested $17.5 million through one of its managed funds and will join Vaderis’ board as an observer.
The size and investor mix are notable for a European rare-disease biotech entering Phase 3. Rather than financing another early-stage proof-of-concept program, the syndicate is backing a company with pivotal development ahead and a potential path to commercialization.
“This milestone reflects the dedication of our patients, investigators, study teams, and advocacy organizations,” Vaderis CEO Azmi Nabulsi said. “Closing this financing and initiating HEROIC as the first Phase 3 study utilizing a molecule specifically developed for HHT marks an exciting new chapter.”
A disease without an approved treatment
HHT affects an estimated one in 3,800 people and is caused by inherited abnormalities in blood-vessel formation. Patients can suffer from recurrent, sometimes severe nosebleeds, chronic anemia and abnormal blood-vessel connections that can lead to serious or life-threatening complications.
Despite the disease burden, there are currently no therapies approved specifically for HHT. Existing management focuses largely on controlling symptoms and complications.
Vaderis’ engasertib is designed to address the underlying vascular biology of the disease. The company has already reported positive proof-of-concept and long-term extension data, including results published in The New England Journal of Medicine. According to Vaderis, the data showed clinically meaningful and sustained improvements across several measures of disease activity.
Those results provide the basis for the next step: HEROIC, a global Phase 3 study intended to establish the efficacy and safety of engasertib and potentially support regulatory approval.
Why the financing matters
For Vaderis, the $152 million is more than a conventional clinical financing. It is intended to provide capital through the company’s potential regulatory filing and approval process.
That changes the risk profile of the program. Phase 3 trials are substantially more expensive than earlier-stage studies, particularly when they are global and target a rare disease population. A sufficiently capitalized balance sheet can allow a company to execute the trial without having to return to the market at a potentially unfavorable point in the biotech financing cycle.
It also gives Vaderis greater strategic flexibility if the Phase 3 program succeeds. The company can potentially approach regulators, prepare commercialization activities and decide whether to retain or partner global rights from a position of greater financial strength. The financing also highlights the increasing willingness of specialist investors to fund late-stage European biotech assets when clinical differentiation and a clear regulatory path are visible.
A Swiss company with a global opportunity
Vaderis is developing engasertib from Switzerland, but the commercial opportunity is global. HHT is a rare disease, yet its lack of approved disease-specific treatment creates a relatively clear unmet medical need.
For investors, the attraction is therefore not simply the size of the patient population. It is the combination of a genetically defined disease, a dedicated therapeutic approach, positive clinical data and a potential first-to-market position.
Christoph Broja, Partner at EQT Life Sciences, said the firm’s conviction was based on the proof-of-concept data and the opportunity to support the company through late-stage development.
“HHT remains a serious, lifelong disease with no approved treatment anywhere in the world,” he said. “We’re pleased to support the Vaderis team as they advance engasertib into Phase 3 with the goal of potentially bringing these patients their first dedicated therapy.” The financing is consequently a significant milestone not only for Vaderis but also for the Swiss biotech sector: a privately held European company has assembled a large international investor syndicate around a late-stage rare-disease program, with the capital designed to carry the asset substantially closer to the market.
The critical test now moves from financing to execution. If HEROIC confirms the earlier clinical signal, Vaderis could move from a Swiss clinical-stage biotech to the company behind the first therapy specifically developed and potentially approved for HHT.
Sign up for our newsletter!
